This blog addresses what BPC-157 is, what the evidence actually shows, and why I do not currently offer it as a treatment at NTXMSK
The result is a new frontier in peptide research that spans traumatic brain injury, stroke recovery, neurodegenerative disease, and the broader pursuit of cognitive resilience
According to the most recent Global Burden of Disease classification system in 2021, in the United States, Alzheimer's disease and other dementias were the 17th leading disease or injury cause of DALYs overall 482 and the leading disease or injury cause for the age group 80 years
It is important to realize that these are unproven claims, and that the use of BPC-157 for these or any other reasons is not supported by medical literature or by any medical associations
Other compounding pharmacies have since stopped openly distributing BPC-157, fearing similar action